In 2018, the National Institute of Aging and Alzheimer’s Association (NIA-AA) modified the diagnosis framework, suggesting that Alzheimer’s disease (AD) biomarkers, including β-amyloid (Aβ) deposition, pathologic tau (T), and neurodegenerative/neuronal injury biomarkers (N), can be added to the A/T/N classification system to improve diagnostic accuracy [1]. The gene discussed is MAPT; the disease is Alzheimer disease.